{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:27:54Z","timestamp":1793608074120,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.anai.2026.02.010","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:07:23Z","timestamp":1772294843000},"page":"671-680.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of background asthma and atopic conditions on prophylaxis and treatment of COVID-19 infection"],"prefix":"10.1016","volume":"136","author":[{"given":"Ruifeng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangnan","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasturi","family":"Talapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Mylonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8936-748X","authenticated-orcid":false,"given":"Gregory P.","family":"Geba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2026.02.010_bib0001","unstructured":"Our World in Data. Cumulative confirmed COVID-19 cases by world region 2024. Accessed November 20, 2024. Available at: https:\/\/ourworldindata.org\/grapher\/cumulative-covid-cases-region"},{"key":"10.1016\/j.anai.2026.02.010_bib0002","unstructured":"Centers for Disease Control and Prevention. Trends in United States COVID-19 deaths, emergency department (ED) visits, and test positivity by geographic area 2024. Accessed November 20, 2024. Available at: https:\/\/covid.cdc.gov\/covid-data-tracker\/#trends_totaldeaths_select_00"},{"key":"10.1016\/j.anai.2026.02.010_bib0003","unstructured":"Centers for Disease Control and Prevention. Underlying conditions and the higher risk for severe COVID-19 2024. Accessed November 20, 2024. Available at: https:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html"},{"issue":"5","key":"10.1016\/j.anai.2026.02.010_bib0004","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.anai.2024.01.011","article-title":"Association between allergic conditions and COVID-19 susceptibility and outcomes","volume":"132","author":"Chen","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"23","key":"10.1016\/j.anai.2026.02.010_bib0005","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with Covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.anai.2026.02.010_bib0006","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent Covid-19","volume":"385","author":"O\u2019Brien","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2026.02.010_bib0007","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ijid.2022.06.045","article-title":"Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19","volume":"122","author":"Isa","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.anai.2026.02.010_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104468","article-title":"Evaluation of the EUROIMMUN anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies","volume":"129","author":"Beavis","year":"2020","journal-title":"J Clin Virol"},{"issue":"11","key":"10.1016\/j.anai.2026.02.010_bib0009","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jamainternmed.2025.4283","article-title":"Azelastine Nasal Spray for prevention of SARS-CoV-2 infections: A Phase 2 randomized clinical trial","volume":"185","author":"Lehr","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"12","key":"10.1016\/j.anai.2026.02.010_bib0010","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.3390\/v16121914","article-title":"Azelastine Nasal Spray in non-hospitalized subjects with mild COVID-19 infection: a randomized placebo-controlled, parallel-group, multicentric, Phase II clinical trial","volume":"16","author":"Meiser","year":"2024","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.anai.2026.02.010_bib0011","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/all.14551","article-title":"Atopic status protects from severe complications of COVID-19","volume":"76","author":"Scala","year":"2021","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2026.02.010_bib0012","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14581","article-title":"Rare atopy in COVID-19 patients or COVID-19 famine in atopic patients?","volume":"34","author":"Naziro\u011flu","year":"2021","journal-title":"Dermatol Ther"},{"issue":"10","key":"10.1016\/j.anai.2026.02.010_bib0013","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1080\/02770903.2020.1789873","article-title":"Is asthma an exclusionary condition for SARS-CoV-2 infection in China? -the relationship between asthma and COVID-19","volume":"58","author":"Ma","year":"2021","journal-title":"J Asthma"},{"key":"10.1016\/j.anai.2026.02.010_bib0014","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6510332","article-title":"The association between allergic rhinitis and COVID-19: a systematic review and meta-analysis","volume":"2022","author":"Xu","year":"2022","journal-title":"Int J Clin Pract"},{"issue":"5","key":"10.1016\/j.anai.2026.02.010_bib0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pulmoe.2020.05.003","article-title":"COVID-19 and asthma: to have or not to have T2 inflammation makes a difference?","volume":"26","author":"Morais-Almeida","year":"2020","journal-title":"Pulmonology"},{"issue":"1","key":"10.1016\/j.anai.2026.02.010_bib0016","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000510953","article-title":"Does asthma increase the mortality of patients with COVID-19?: a systematic review and meta-analysis","volume":"182","author":"Wang","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.02.010_bib0017","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jaci.2020.07.018","article-title":"Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19","volume":"146","author":"Wang","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.02.010_bib0018","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2020.08.008","article-title":"Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study","volume":"146","author":"Yang","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.02.010_bib0019","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors","volume":"9","author":"Han","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"6","key":"10.1016\/j.anai.2026.02.010_bib0020","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jaip.2020.04.014","article-title":"Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection","volume":"8","author":"Lipworth","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2026.02.010_bib0021","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jaci.2020.07.001","article-title":"The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection","volume":"146","author":"Copaescu","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2026.02.010_bib0022","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaci.2020.09.017","article-title":"Asthma-associated risk for COVID-19 development","volume":"146","author":"Skevaki","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.02.010_bib0023","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/s12890-022-02230-5","article-title":"Patients with allergic asthma have lower risk of severe COVID-19 outcomes than patients with nonallergic asthma","volume":"22","author":"Murphy","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.anai.2026.02.010_bib0024","series-title":"Association between asthma and severe outcomes to COVID-19","author":"Chen","year":"2024"},{"issue":"7","key":"10.1016\/j.anai.2026.02.010_bib0025","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1007\/s00405-020-06408-7","article-title":"ACE2 expression in allergic airway disease may decrease the risk and severity of COVID-19","volume":"278","author":"Chhapola Shukla","year":"2021","journal-title":"Eur Arch Oto-rhino-laryngol"},{"issue":"4","key":"10.1016\/j.anai.2026.02.010_bib0026","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/17476348.2021.1850275","article-title":"Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?","volume":"15","author":"Rogliani","year":"2021","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2026.02.010_bib0027","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1164\/rccm.202003-0821OC","article-title":"COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids","volume":"202","author":"Peters","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"17","key":"10.1016\/j.anai.2026.02.010_bib0028","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.3390\/cells11172743","article-title":"Immune determinants of viral clearance in hospitalised COVID-19 patients: reduced circulating na\u00efve CD4+ T cell counts correspond with delayed viral clearance","volume":"11","author":"Zlei","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.anai.2026.02.010_bib0029","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3390\/vaccines11020408","article-title":"Innate and adaptive immunity during SARS-CoV-2 infection: biomolecular cellular markers and mechanisms","volume":"11","author":"Brown","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.anai.2026.02.010_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2023.101828","article-title":"T cell control of SARS-CoV-2: when, which, and where?","volume":"70","author":"Diniz","year":"2023","journal-title":"Semin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.02.010_bib0031","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10238-024-01405-0","article-title":"Efficacy and safety of glucocorticoids in the treatment of COVID-19: a systematic review and meta-analysis of RCTs","volume":"24","author":"Ye","year":"2024","journal-title":"Clin Exp Med"},{"issue":"5","key":"10.1016\/j.anai.2026.02.010_bib0032","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cmi.2023.12.028","article-title":"Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence","volume":"30","author":"Sweeney","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.anai.2026.02.010_bib0033","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2026.02.010_bib0034","unstructured":"Food and Drug Administration. FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19 2021. Accessed August 25, 2021. Available at:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19"},{"key":"10.1016\/j.anai.2026.02.010_bib0035","unstructured":"Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for treatment of COVID-19 2020. Accessed August 25, 2021. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19"},{"issue":"1","key":"10.1016\/j.anai.2026.02.010_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.focus.2022.100005","article-title":"Patient self-report superior to electronic medical record abstraction for identifying positive COVID-19 symptoms at illness onset","volume":"1","author":"Mockler","year":"2022","journal-title":"AJPM Focus"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626000700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626000700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:43:22Z","timestamp":1793605402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626000700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1081120626000700"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.02.010","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of background asthma and atopic conditions on prophylaxis and treatment of COVID-19 infection","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}